Sensus Healthcare, Inc. (NASDAQ:SRTS) is a cutting-edge medical device company dedicated to transforming the treatment of non-melanoma skin cancers, keloids, and other dermatologic conditions through advanced, non-invasive technologies. Founded in 2010 and headquartered in Boca Raton, Florida, Sensus has established itself as a global innovator in superficial radiation therapy (SRT), offering patient-friendly alternatives to traditional surgical treatments. With a mission to improve patient outcomes while reducing the cost and complexity of care, Sensus Healthcare is redefining how clinicians approach skin cancer and scar treatment in both the United States and international markets.
The company’s flagship product line—SRT-100™, SRT-100+™, and SRT-100 Vision™—utilizes precise, low-dose radiation to target basal cell carcinoma, squamous cell carcinoma, and other dermatologic concerns without the need for incisions, anesthesia, or post-surgical recovery. These FDA-cleared systems are especially beneficial for elderly or high-risk patients who are not ideal candidates for surgery, offering a safe, effective, and cosmetically superior treatment option that can be performed in-office. As outpatient and value-based care models gain momentum across the healthcare industry, Sensus’ minimally-invasive platform is emerging as a preferred solution for both clinicians and patients.
Sensus Healthcare’s commitment to innovation extends beyond oncology. The company is actively developing next-generation therapies, including its TransDermal Infusion (TDI) platform equipped with Sentinel™ IT Solutions for enhanced precision and remote monitoring. These advancements are part of a broader strategy to expand the company’s footprint into adjacent markets, improve care delivery, and unlock new revenue streams through both product sales and recurring service agreements.
At the heart of Sensus’ growth strategy is its Fair Deal Agreement (FDA) program—an innovative leasing model that lowers the barrier to adoption for healthcare providers. By offering SRT systems with flexible terms, built-in reimbursement guidance, and operational support, the FDA program enables dermatology practices to adopt advanced technology without the upfront capital burden. With more than 130 installations nationwide, the program continues to grow, driving repeat business and long-term customer relationships.
With a strong balance sheet, no debt, and a history of profitability, Sensus Healthcare is well-positioned for sustained expansion in the $5+ billion skin cancer treatment market. The company’s products are currently installed in hospitals, dermatology clinics, outpatient centers, and academic institutions across North America, Asia, and the Middle East. In a healthcare landscape increasingly focused on non-invasive solutions, patient satisfaction, and clinical efficiency, Sensus Healthcare remains a standout player—pioneering a smarter, safer, and more accessible future for skin cancer care and dermatologic health.
First Quarter 2025: Financial Highlights and Strategic Execution
Sensus Healthcare entered 2025 with a clear commitment to investing in long-term growth. For the first quarter ended March 31, 2025, the company reported revenues of $8.3 million, shipping 21 SRT systems—15 of which were delivered to a large domestic customer and one internationally. Despite a year-over-year revenue decline from $10.7 million in Q1 2024, the company’s performance exceeded internal expectations and beat Wall Street estimates. Most importantly, the company is forecasting profitability for each of the next three quarters and full-year 2025, indicating strong confidence in sales momentum, operational efficiency, and demand trajectory.
Sensus saw a 65% quarter-over-quarter increase in patient treatment volume through its FDA-based (Fair Deal Agreement) systems, a metric that reflects both expanding utilization and growing clinician endorsement. With more than 130 dermatology practices now participating in the FDA program, the company expects these recurring channels to meaningfully contribute to revenue in the second half of the year. Management also reaffirmed guidance to secure 3–5 additional multisite FDA customers in 2025.
CHECK THIS OUT: Gilead Sciences (GILD) is a Top Long-Term Biotech Investment for 2025 and CEL-SCI Corporation: Leading the Future of Cancer Immunotherapy with Multikine®.
Building Awareness and Pipeline Expansion
One of the defining features of Q1 2025 was Sensus’ aggressive outreach strategy. The company showcased its flagship and pipeline products at the Winter Clinical Dermatology Conference and the American Academy of Dermatology (AAD) Annual Meeting. A highly attended event at AAD featuring Olympic gold medalist Katie Ledecky generated significant customer engagement and interest in the SRT platform. In anticipation of this increased demand, Sensus placed new orders for additional system inventory to meet near-term shipment needs.
The company is also making significant headway in research and development. It is finalizing the next-generation TransDermal Infusion (TDI) product integrated with Sentinel™ IT Solutions, enhancing its product ecosystem while continuing to refine IG-SRT (Image-Guided Superficial Radiation Therapy) capabilities. Management also invested in lobbying efforts to promote recognition of IG-SRT by regulatory agencies, aiming for broader reimbursement and institutional adoption in the U.S. healthcare system.
Profitability Outlook and Operational Discipline
While Q1 2025 reflected a net loss of $2.6 million, or $(0.16) per share, this is largely attributable to ramped-up investments in marketing, product development, trade show appearances, and regulatory advocacy. Selling and marketing expenses rose to $2.2 million from $1.3 million in the prior year, while R&D expenses tripled to $2.6 million. However, these investments are expected to deliver tangible returns across the remainder of the year.
The company remains fiscally sound, with $19.1 million in cash and no debt as of March 31, 2025. Prepaid inventory stood at $5.7 million—up from $3.3 million at year-end 2024—signaling strategic planning to fulfill rising demand. Gross margin was 53.0% in Q1 2025 compared to 62.6% the year prior, primarily due to lower system sales and increased servicing costs, but the company expects margin recovery as revenue scales in Q2 and beyond.
Adjusted EBITDA for Q1 2025 was negative $2.5 million versus a positive $3.0 million in the same quarter of 2024. However, this swing is viewed by management as a temporary trade-off, necessary for accelerating market penetration, raising brand awareness, and laying the groundwork for sustained profitability. With multi-quarter profitability forecasted, margin and cash flow improvements are expected to materialize quickly.
Strategic Tailwinds and Market Positioning
What makes Sensus particularly attractive is its defensible position in a niche but growing market. Skin cancer remains the most common cancer in the U.S., with over 5 million cases treated annually. Sensus provides a non-invasive alternative that preserves healthy tissue, delivers excellent cosmetic outcomes, and is suitable for elderly patients or those with co-morbidities that may preclude surgery. With healthcare moving toward outpatient, patient-centric care, Sensus’ model aligns perfectly with macro trends.
Additionally, the company’s diversified go-to-market strategy—encompassing direct sales, FDA leasing programs, trade show marketing, and government affairs outreach—provides multiple levers to drive both immediate and long-term growth. Its international presence, growing reseller network, and continuous engagement at medical conferences all contribute to a strong brand identity in a market that rewards clinical innovation and service integration.
Conclusion: Why Sensus Healthcare (SRTS) Deserves Bullish Attention
Sensus Healthcare stands at an inflection point. After a foundational first quarter marked by investment and positioning, the company is on the cusp of executing a full-year profitability turnaround in 2025. Its SRT systems are gaining traction not only for their clinical effectiveness but also for their economic and operational efficiency—critical attributes in today’s cost-conscious healthcare landscape.
With a clean balance sheet, growing recurring revenue base, and near-term catalysts in both product and customer pipeline, Sensus offers a compelling medtech growth story. The company’s strategy of pairing clinical efficacy with patient-friendly solutions, while also building an ecosystem around long-term service revenue, sets it apart in the dermatology and radiation oncology segments.
For investors seeking exposure to under-the-radar healthcare innovators with strong upside potential, scalable platforms, and recurring revenue growth, Sensus Healthcare (NASDAQ: SRTS) presents a timely and promising opportunity.
READ ALSO: Incyte (INCY) is the Next Big Biotech Winner and Bluebird Bio (BLUE) Posts 108% Revenue Growth in Q1 2025 Amid Acquisition Buzz.
